Infinimmune
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
$75MSeries A
Role not disclosedMG
Merck Global Health Innovation Fund
Activity from announced rounds
Activity in this selectionAI
Merck Global Health Innovation Fund is the US Merck/MSD investment fund identified in N-Power and Merck Digital Sciences Studio material.
Recorded funding activity
N-Power combines oncology care with trial-data services. DropGenie miniaturizes gene-editing workflows, while Infinimmune develops antibody medicines. The fund remains separate from the Merck parent and Germany’s Merck and M Ventures.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $75M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionDropGenie
Miniaturizes gene editing workflows to enable direct edits on primary patient cells for cell therapy and drug discovery
UndisclosedSeed+
Role not disclosed